ILLUMINA, INC.
Customers
10
3 disclosed, 5 federal agencies, 2 prime contractors
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Federal obligations
$21.6M
FY2026 · USAspending.gov
Latest period
Dec 31, 2025
10-K filed 2026-02-27
Customers 3
Companies ILMN discloses as major customers, as a share of ILMN revenue. 3 active, 0 lapsed.
| Company | % of ILMN revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| GH Guardant Health, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-19 |
We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, software, instruments and materials that we use in our laboratory operations. | ||||||
| NTRA Natera, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-27 |
In addition, if we obtain FDA clearance, approval or de novo classification for any of our tests as an in vitro diagnostic, or IVD, such issues with suppliers or the components that we source from suppliers could affect our commercialization efforts for such an IVD, as further described in the risk factor entitled “Regulatory and Compliance Risks—If the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls.” Our failure to maintain a continued supply of components, or a supply that meets our quality control requirements, or changes to or termination of our agreements or inability to renew our agreements with these parties or enter into new agreements with other suppliers, particularly in the case of sole suppliers such as Streck and Illumina, could result in the loss of access to important components of our tests and impact our test performance or affect our ability to perform our tests in a timely manner or at all, which could impair, delay or suspend our commercialization activities. | ||||||
| TEM Tempus AI, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-24 |
We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, instruments and materials that we use in our laboratory operations. | ||||||
Federal contracts 5
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $23.5M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Health and Human Services
National Institutes of Health |
$13.3M | FY 2026 | 189 | $32.0M → $24.0M → $21.8M → $13.3M | 75N98026F00009 |
ILLUMINA KITS FOR NIH INTRAMURAL SEQUENCING CENTER (NISC) POTS NUMBER : 26-003154 | |||||
| Department of Agriculture
Food Safety and Inspection Service |
$4.9M | FY 2026 | 62 | $7.0M → $5.8M → $6.0M → $4.9M | 123A9426F0047 |
PURCHASE OF 7 MISEQ I100S TO PERFORM WHOLE GENOME SEQUENCING (WGS) ON ALL FOODBORNE PATHOGENS ISOLATED AND CONFIRMED FROM FSIS INSPECTED PRODUCTS OFF USDA-WIDE CONTRACT 1232SA25D0004 | |||||
| Department of Veterans Affairs
Department of Veterans Affairs |
$2.0M | FY 2026 | 26 | $1.9M → $1.9M → $2.0M | 36C10B25C0055 |
ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM | |||||
| Department of Defense
Department of the Army |
$1.9M | FY 2025 | 26 | $3.1M → $3.9M → $1.9M | W911QX25PA097 |
ONE (1) DEOXYRIBONUCLEIC ACID (DNA) SEQUENCER SYSTEM | |||||
| Department of the Interior
Departmental Offices |
$1.4M | FY 2026 | 25 | 140D0426P0102 | |
MAINTENANCE AND SERVICE CONTRACT FOR VARIOUS GOVERNMENT-OWNED ILLUMINA SEQUENCING PLATFORMS AND ANCILLARY EQUIPMENT | |||||
Federal subcontracts received 2
Prime contractors that subcontracted federal work to this company. From USAspending.gov subaward reports; amounts are as reported by the prime contractor, latest report per subaward, $500K+ a year.
| Company | Subawards | Fiscal year | Count | Trend | Largest subaward |
|---|---|---|---|---|---|
| The Johns Hopkins Health System Corporation | $2.1M | FY 2025 | 2 | 75N92024F00001 | |
ILLUMINA DNA/RNA UD INDEXES SET D, TAGM | |||||
| Battelle National Biodefense Institute, LLC | $645.5K | FY 2025 | 6 | HSHQDC15C00064 | |
PURCHASE NEXTSEQ 2000 SEQUENCING SYSTEM INSTRUMENT | |||||
Alerts are coming
Get an email when ILMN's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.